STEMTECH CORP - STEK STOCK NEWS

Stemtech Corporation has appointed Mr. I. Tufan Obuz as Chief Administrative Officer (CAO), a key addition to the executive management team. Mr. Obuz, a CPA, will oversee global accounting and finance activities, ensuring compliance and operational efficiency. This strategic hire aims to strengthen financial resources and improve reporting compliance for the publicly traded company (OTCQB:STEK). CEO Charles Arnold emphasized Mr. Obuz's extensive experience, which will benefit Stemtech's global operations. The company, founded in 2018, specializes in stemceutical products and has seen significant growth since transitioning to public trading in 2021.

Stemtech (OTCQB: STEK) has secured a $7 million investment to facilitate its expansion into Colombia and Ecuador. The funding will eliminate the company's largest credit facility and support its strategic growth plan, Vision 2023. Historically, Stemtech recorded over $10 million in sales in Colombia from 2009 to 2017, and plans to introduce a full product range in Ecuador, where demand is high. The global stem cell market is projected to grow from $5.14 billion in 2022 to $6.45 billion in 2023, with a CAGR of 25.5%. This investment reflects strong confidence in Stemtech’s management and potential for increased revenues with innovative products.

Stemtech Corporation (OTCQB: STEK) has announced a series of Business Academies for Independent Business Partners (IBPs) in 2023, scheduled in Mexico, the United States, and Taiwan. The first event will occur in Agua Calientes, Mexico from May 4-6, followed by a gathering in Las Vegas, NV in June, and concluding in Taiwan in October. These academies, part of the Stemtech 360 program, focus on training and promoting new products, including the recent introduction of Cellect One Rapid Renew Stem Cell Peptide Night Cream. This initiative aims to enhance IBPs' financial opportunities and is expected to support business growth globally.

Stemtech Corporation (OTCQB:STEK) has launched two new products in Taiwan as part of its Stemtech 360 program: Cellect One™ Skin Tightening and Repairing Serum and OraStem^® Toothpaste. These additions aim to enhance their existing product offerings and are designed specifically for the Asian market. The company anticipates that these products will drive greater monthly sales than their peak in December 2022. Additionally, Stemtech Taiwan was recognized by the Taiwanese government for ethical business practices. Stemtech focuses on stem cell nutrition and offers income-earning opportunities for its Independent Business Partners.

Stemtech Corporation (OTCQB: STEK) has initiated the registration process for its products as part of its expansion into Colombia, aiming to establish an office in Bogotá. This decision follows requests from Field leaders during a Leadership Event in December 2022 and aligns with the company's 'Just One More' concept. CEO Charles S. Arnold highlighted Colombia's potential market for their stemceutical™ products, particularly emphasizing the new Cellect One™ Rapid Renew Stem Cell Peptide Night Cream. The initiative is part of the 2023 strategic business plan, focusing on growth in Latin America, leveraging advancements in their AdvanceOffice mobile app for better communication and recruitment.

Stemtech Corporation (OTCQB:STEK) announced the appointment of Claude Ayache as Vice President of Finance for its US subsidiary. He will also continue his responsibilities with Stemtech Canada until relocating to Florida. Ayache's expanded role will include strategic collaboration with the executive team and managing financial reporting. His expertise has already contributed to the company's improved regulatory reporting and the acquisition of Life Factor Research. Stemtech has risen to 11th place in the rankings of the top network marketing companies in business momentum, reflecting its growth strategy and investment in infrastructure.

Stemtech Corporation (OTCQB: STEK) has achieved a remarkable rise in its ranking, moving from 159th to 11th in the Business For Home 'Momentum' category, demonstrating significant growth in the network marketing industry. This leap validates Stemtech's strategic efforts, including the launch of their Stemtech AdvanceOffice mobile app and the introduction of the CellectOne™ Rapid Renew Stem Cell Peptide Night Cream. CEO Charles S. Arnold emphasized that this achievement reflects the company's ongoing upward trend, supported by its Independent Business Partners' enthusiasm and new product development initiatives set forth in their VISION 2023 strategy.